 This is a Phase 3, multicenter, open-label, safety and tolerability study of continuous apomorphine infusion in subjects with advanced Parkinsons Disease PD whose motor fluctuations remain unsatisfactory with levodopa or levodopacarbidopa and at least one other class of drugs or mode of therapy for PD. 